SEC Comment Letter for ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Oct 19, 2022
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: Oct. 19, 2022 · CIK: 0001281895 · Accession: 0000000000-22-011509
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267871
Letter
United States securities and exchange commission logo October 19, 2022 Gaurav Shah, M.D. Chief Executive Officer Rocket Pharmaceuticals, Inc. 9 Cedarbrook Drive Cranbury, NY 08512 Re:Rocket Pharmaceuticals, Inc. Registration Statement on Form S-4 Filed October 13, 2022 File No. 333-267871 Dear Gaurav Shah: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John T. Haggerty, Esq.
Show Raw Text
United States securities and exchange commission logo
October 19, 2022
Gaurav Shah, M.D.
Chief Executive Officer
Rocket Pharmaceuticals, Inc.
9 Cedarbrook Drive
Cranbury, NY 08512
Re:Rocket Pharmaceuticals, Inc.
Registration Statement on Form S-4
Filed October 13, 2022
File No. 333-267871
Dear Gaurav Shah:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John T. Haggerty, Esq.